Latest Articles

Publication Date
A Ureteral DE-lemma: Obstructive Hydroureteronephrosis in the Setting of Deep Endometriosis.

Endometriosis is a chronic inflammatory condition affecting 10% to 15% of reproductive-aged women. The urinary tract is the second most common extragenital site of endometriosis after the gastrointestinal tract, with …

Published: June 24, 2026, midnight
Palbociclib Plus Anastrozole Is Safe and Effective in ER+ Recurrent Endometrial Cancer - OncLive

Palbociclib Plus Anastrozole Is Safe and Effective in ER+ Recurrent Endometrial Cancer OncLive

Published: June 19, 2026, 1:08 p.m.
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer - OncLive

Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer OncLive

Published: June 17, 2026, 9:11 p.m.
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post

Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post

Published: June 3, 2026, 2:49 p.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress

Published: June 1, 2026, 8 p.m.
Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients - News-Medical

Pembrolizumab combination therapy improves survival in recurrent endometrial cancer patients News-Medical

Published: May 30, 2026, 2:16 a.m.
Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer - OncLive

Pembrolizumab Plus Chemotherapy Shows Long-Term OS Benefit in Advanced/Recurrent Endometrial Cancer OncLive

Published: May 29, 2026, 11:57 p.m.
The periodontal-female reproductive axis and infertility: a scoping review of epidemiological and mechanistic evidence.

Periodontitis is a prevalent chronic inflammatory disease with recognized systemic implications. Its potential link to female reproductive disorders, including infertility, endometriosis, and recurrent implantation failure (RIF), has attracted growing attention, …

Published: May 28, 2026, midnight
New drug approach offers hope for patients with recurrent aggressive cancers - AOL.com

New drug approach offers hope for patients with recurrent aggressive cancers AOL.com

Published: May 25, 2026, 7:45 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!